Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty

Launched by KCI USA, INC · Jun 23, 2011

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject must be ≥ 18 years of age
• • 2. Subject must, at the treating physician's determination and definition, be an appropriate Candidate for primary total hip or knee arthroplasty
• • 3. Subjects who undergo primary total knee or hip arthroplasty must have a linear or semi-linear incision whose length and curvature should fit within the dimensions bound by the polyurethane foam (10 inches in length by 2.5 inches in width)
• • 4. Subject is able and willing to provide written informed consent and comply with visit schedule
• • 5. Subject must agree to avoid application of tanning lotions or exposure of ultraviolet radiation from sun or artificial sources such as a tanning bed on operative area for the duration of study participation
• • 6. Subject must not be pregnant if of child-bearing potential, or otherwise must be surgically sterilized or unable to conceive. All females, regardless of child-bearing potential, will receive a urine hCG test 2 weeks prior to surgery and the test result must be negative for pregnancy.
• • 7. Subjects who are of child-bearing potential must be utilizing an acceptable method of birth control (eg, birth control pills, condom with spermicide, diaphragm with spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc) and be willing to continue birth control for duration of study participation. If birth control method is the form of birth control pills, shots, implants skin patches, or IUD, the method must have been utilized for at least 30 days prior to study participation.
• • 8. Subject must be willing to wear loose fitting clothing for duration of treatment period
• • 9. Subject must be willing to comply with visit schedule for the duration of the study
• Exclusion Criteria:
• • 1. Positive pregnancy test confirmed by hCG in urine
• • 2. Current or past (30 days prior to surgery) within time of screening attempts to become pregnant
• • 3. Current local or systemic infection (eg, skin infections, sinus infections, urinary tract infection, sepsis, etc)
• • 4. Current or past (14 days prior to surgery) within time of screening topical treatments on operative area (eg, laser hair or tattoo removal, sunless tanning lotions)
• • 5. Current or past (14 days prior to surgery) steroid topical therapies on operative area
• • 6. Current or past (30 days prior to surgery) use of oral steroids (NOTE: Use of non-topical, ophthalmic or aerosol types of steroids (ie, inhaled corticosteroids) are permitted at screening and throughout the clinical trial)
• • 7. Current or past (72 hours prior to surgery) within surgery use of antihistamines
• • 8. Current or past (30 days prior to surgery) within time of screening use of oral Tetracycline or AcutaneTM or topical Tetracycline or AcutaneTM on the operative area
• • 9. Presence of skin lesions or abnormalities on operative area
• • 10. Current or past malignancy requiring immunosuppressant therapy or chemotherapy within 5 years within time of screening
• • 11. Presence of excessive skin folds on operative area
• • 12. Intentional exposure of the operative area to ultraviolet radiation (14 days prior to surgery) within time of screening (ie, sunbathing or tanning bed)
• • 13. Presence of sunburned or peeling skin on operative area
• • 14. Tattoos on operative area
• • 15. Presence of severe, raised scar tissue on operative area which may interfere with pre and post skin evaluation assessments
• • 16. Presence of an open wound prior to the index surgical procedure on operative area
• • 17. Reported alcohol (≥ 3 drinks per day) or drug abuse within the past 6 months
• • 18. Topical hypersensitivity or allergy to any disposable components of the dressing system (eg, silver, polyurethane, polyester, or acrylic adhesive)
• • 19. Topical hypersensitivity or allergy towards any medical adhesive
• • 20. Current enrollment or past participation in this clinical study or any other study within ≤30 days
• • 21. Any systemic or local active dermatological disease that might interfere with the evaluation of the operative area (eg, Meleney's ulcer, scleroderma, chronic urticaria, psoriasis, skin cancer, eczema, seborrhea, or malignancy)
• • 22. Connective tissue disease or collagen vascular disease (eg, Ehlers-Danlos syndrome, systemic lupus erythematosus, rheumatoid arthritis)
• • 23. Current or history of hematological disorders or conditions (eg, polycythemia vera, thrombocythemia, sickle-cell disease)
• • 24. Any Subject with conditions which can potentially result in abnormally pigmented skin (eg, melasma, vitiligo, pityriasis versicolor)
• • 25. Inability or refusal to wear loose fitting clothing for the duration of the treatment period
• • 26. Subjects in whom orthopaedic reconstruction is required in addition to total hip or knee arthroplasty
• • 27. Subjects who are having the total hip or knee arthroplasty as a result of acute orthopaedic trauma
• • 28. Subjects who have incurred acute orthopaedic trauma (ie, hip fracture) recently or at any time
• • 29. Subjects who have either acute or chronic open/active wounds present (including biopsies, ulcerations, etc)
• • 30. Subjects in whom the index procedure is a revision of a total hip or knee arthroplasty
• • 31. Subjects in whom the primary or partial total hip or knee arthroplasty would also be performed on the contra lateral knee or hip at the same time